<DOC>
	<DOCNO>NCT01551446</DOCNO>
	<brief_summary>This study evaluate variability several pharmacodynamic measure kidney function , cardiovascular function , cerebral perfusion , haemodynamics .</brief_summary>
	<brief_title>Pilot Assessment Effects Bardoxolone Methyl Renal Perfusion , Systemic Haemodynamics Cardiac Function Patients With Chronic Kidney Disease Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Screening eGFR ≥15.0 ≤60.0 mL/min/1.73 m2 ; 2 . A history type 2 diabetes ; diagnosis make ≥ 30 year age ( diabetes develop young age , fast Cpeptide level must ≥ 0.1 ng/mL confirm type 2 diabetes ) ; 3 . Male female patient least 18 year age ; 4 . Treatment angiotensin convert enzyme ( ACE ) inhibitor and/or angiotensin II receptor blocker ( ARB ) least 6 week prior Study Day 1 . The dosage ACE inhibitor and/or ARB must stable 2 week prior and/or screen ( i.e. , change dosage medication ) . Patients take ACE inhibitor and/or ARB , take ACE inhibitor and/or ARB level goal dose set K/DOQI guideline must document medical contraindication ( e.g. , hyperkalemia , hypotension ) , investigator must provide discuss medical monitor prior Study Day 1 . Patients take ACE inhibitor and/or ARB medical contraindication must discontinue treatment least 8 week prior Study Day 1 ; 5 . Mean systolic blood pressure ( SBP ) ≤160 mmHg ≥105 mmHg mean diastolic blood pressure ( DBP ) ≤90 mmHg screening ; mean SBP mean DBP ( determine average three reading ) must within described range screening period ; 6 . Willing practice method birth control ( male partner childbearing potential female childbearing potential ) screening , take study drug least 30 day last dose study drug ingest ; 7 . Serum magnesium level must ≥1.3 mEq/L ( 0.65 mmol/L ) screening period ; 8 . Willing able cooperate aspect protocol ; 9 . Willing able give write informed consent study participation . 1 . Type 1 diabetes mellitus ( juvenile onset ) . If history diabetic ketoacidosis exists , fast Cpeptide level must confirm type 2 diabetes ; 2 . Known nondiabetic renal disease ( e.g. , know polycystic kidney disease , family history hereditary form kidney disease , congenital absence one kidney ) [ nephrosclerosis superimpose diabetic kidney disease acceptable ] ; 3 . Ongoing clinical investigation evidence ( e.g. , unexplained hematuria red blood cell white blood cell cast ) suggest nondiabetic renal disease nephrosclerosis ; 4 . History renal donation , transplant plan transplant living donor study ; 5 . Albumin/creatinine ( ACR ) screen period great 3500 mg/g ( 395.5 mg/mmol ) ; 6 . Hemoglobin A1c level &gt; 11.0 % ( 97 mmol/mol ) screening period ; 7 . Acute dialysis acute kidney injury within 12 week prior screen screen ; 8 . Clinical sign and/or symptom uremia expect need renal replacement therapy within 6 week follow Study Day 1 , assess investigator ; 9 . Recently active cardiovascular disease define : Unstable angina pectoris within 12 week Study Day 1 ; Myocardial infarction , coronary artery bypass graft surgery , percutaneous transluminal coronary angioplasty/stent within 12 week Study Day 1 ; Cerebrovascular accident , include transient ischemic attack within 12 week Study Day 1 ; 10 . Clinical diagnosis severe obstructive valvular heart disease severe obstructive hypertrophic cardiomyopathy ; 11 . Atrioventricular block , 2o 3o ; 12 . Administration contrast agent may induce nephropathy within 30 day prior Study Day 1 plan study ; 13 . Systemic immunosuppression 2 week , cumulatively , within 12 week prior Study Day 1 anticipate need immunosuppression study ; 14 . Total bilirubin , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) level great upper limit normal ( ULN ) alkaline phosphatase level &gt; 2x ULN ANY screen laboratory test result ; 15 . Female patient pregnant , intend become pregnant study , nursing ; 16 . BMI &lt; 18.5 kg/m2 ; 17 . Known hypersensitivity component study drug ; 18 . Current history drug alcohol abuse , assess investigator ; 19 . Clinically significant infection require intravenous administration antibiotic hospitalization within 6 week prior screen period ; 20 . Hepatitis B surface antigen positive ; 21 . Diagnosis treatment malignancy past 5 year , exclude nonmelanoma skin cancer carcinoma situ cervix , condition highly likely transform malignancy course study ; 22 . A clinical condition , judgment investigator , could potentially pose health risk patient involve study ; 23 . Participation clinical study involve intervention within 30 day prior Study Day 1 , concurrent participation study , participation prior clinical study involve bardoxolone methyl form ; 24 . Unable understand verbal write information English ; 25 . Mental incapacity consent ; 26 . Contraindications MRI ( implant , pace maker , claustrophobia ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>